Redeye returns with adjusted estimates and a new Base Case following the Q2’21 report. According to us, the shellshock -30% share price drop was an overreaction, and the new levels should prove favorable for investors buying into the long-term story.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Integrum - Q2'21 report reaction non-reflecting long-term potential

© Modular Finance, source Nordic Press Releases